Loading...
•
Sep 30, 2020
UroGen Q3 2020 Earnings Report
UroGen reported third quarter 2020 financial results and recent corporate developments.
Key Takeaways
UroGen Pharma reported Jelmyto net product revenue of $3.5 million in the third quarter of 2020, its first full quarter of commercialization. The company's research and development expenses were $10.2 million, and SG&A expenses were $22.1 million. UroGen reported a net loss of $28.8 million, or $1.31 per share, and cash and cash equivalents totaled $125.5 million as of September 30, 2020.
Jelmyto achieved net product revenue of $3.5 million in the first full quarter of commercialization.
Top-line results from UGN-102 OPTIMA II Phase 2b trial are expected by year end 2020.
The company remains on track to initiate Phase 3 ATLAS trial by year end.
Management team was expanded to drive platform expansion and growth strategies.
UroGen
UroGen
UroGen Revenue by Segment
Revenue by Segment
JELMYTO Revenue
CapyFin.com Forward Guidance
UroGen expects 2020 total operating expense in the range of $138 to $143 million, including non-cash share-based compensation expense of $25 to $29 million, subject to market conditions. Other non-operating income for 2020 is anticipated to be approximately $2.0 million.